The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Fruquintinib plus paclitaxel versus paclitaxel as second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma (FRUTIGA): A randomized, multicenter, double-blind, placebo-controlled, phase 3 study.
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; HenRui; Junshi Biosciences; KYM Biosciences; Merck Serono; Roche
 
Feng Wang
No Relationships to Disclose
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Weijian Guo
No Relationships to Disclose
 
Tianshu Liu
No Relationships to Disclose
 
Jin Li
No Relationships to Disclose
 
Shukui Qin
No Relationships to Disclose
 
Yuxian Bai
No Relationships to Disclose
 
Zhendong Chen
No Relationships to Disclose
 
Jufeng Wang
No Relationships to Disclose
 
Yueyin Pan
No Relationships to Disclose
 
Yongqian Shu
No Relationships to Disclose
 
Fuyou Zhao
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Feng Ye
No Relationships to Disclose
 
Kangsheng Gu
No Relationships to Disclose
 
Tao Zhang
No Relationships to Disclose
 
Hongming Pan
No Relationships to Disclose
 
Haijun Zhong
No Relationships to Disclose
 
Weiguo Su
Employment - HUTCHMED
Leadership - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED